Phase 3 Trial Will Examine Mesdopetam as Treatment for Levodopa-induced Dyskinesia
Integrative Research Laboratories (IRLAB) is planning a Phase 2b/3 clinical trial of its investigational therapy mesdopetam (IRL790) to evaluate the therapy’s ability to reduce levodopa-induced dyskinesia (involuntary muscle movements)Â in people with Parkinson’s disease. IRLAB is in the process of preparing applications to relevant regulatory agencies, with…